Ginkgo Bioworks (DNA) 10-K/A 31 Aug 22 2021 FY Annual report (amended) Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 17, 2022	Jun. 30, 2021
Document Information [Line Items]
Document Type	10-K/A
Amendment Flag	true
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Central Index Key	0001830214
Current Fiscal Year End Date	--12-31
Entity File Number	001-40097
Entity Registrant Name	GINKGO BIOWORKS HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-2652913
Entity Address, Address Line One	27 Drydock Avenue
Entity Address, Address Line Two	8th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	877
Local Phone Number	422-5362
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Interactive Data Current	Yes
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Entity Public Float			$ 250.5
Amendment Description	This Amendment No. 1 to the Annual Report on Form 10-K/A (this “Amendment”) amends the Annual Report on Form 10-K for the year ended December 31, 2021 (the “Original Report”) of Ginkgo Bioworks Holdings, Inc. (the “Company”), which was filed with the Securities and Exchange Commission (“SEC”) on March 29, 2022. This Amendment is being filed for the purpose of providing separate financial statements of Allonnia, LLC (“Allonnia”) in accordance with Rule 3-09 of Regulation S-X. Allonnia was a significant investee under Rule 3-09 for the Company’s fiscal year ended December 31, 2019, but not for the fiscal years ended December 31, 2020 and 2021. Allonnia’s audited financial statements for the fiscal years ended December 31, 2021 and 2020 and for the period from November 27, 2019 (inception) through December 31, 2019, are filed as Exhibit 99.1 hereto and are included as financial statement schedules in Item 15, “Exhibits, Financial Statement Schedules,” of this Amendment. The consent of Wolf & Company, P.C., independent public accounting firm for Allonnia, is filed as Exhibit 23.2 to this Amendment. In addition, this Amendment includes an updated exhibit index in respect thereof and certifications under Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Except as described above, this Amendment does not update or modify any other information presented in the Original Report and does not reflect events occurring after the Original Report’s filing date of March 29, 2022. Accordingly, this Amendment should be read in conjunction with the Company’s other filings made with the SEC subsequent to the filing of the Original Report.
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Boston, Massachusetts
Common Class A [Member]
Document Information [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	DNA
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		1,080,456,818
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol	DNA.WS
Security Exchange Name	NYSE
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		391,147,458
Non-voting Class C common stock [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		288,000,000